Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) — PALISADE  

Familial Chylomicronemia Clinical Trial

Official title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome

Status Active, not recruiting

Clinical Trial Summary

The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Familial Chylomicronemia
• Hyperlipoproteinemia Type I

• NCT number: NCT05089084
• Study type: Interventional
• Source: Arrowhead Pharmaceuticals
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: January 11, 2022
• Completion date: April 2026